China approved its first COVID-19 vaccine for general public use on Thursday, a shot developed by an affiliate to state-backed Sinopharm, after the developer said the vaccine showed 79.34% efficacy based on an interim analysis of late-stage clinical trials. That rate is lower than the 86% rate for the same vaccine reported by the United Arab Emirates on Dec 9. "Therefore, there were differences between the comprehensive multi-country data we reviewed and the protection rate data previously evaluated by the UAE and Bahrain," Global Times quoted Yang as saying in a report published on Thursday. "But these two results are both real and valid," Yang said, without offering further details for the data. CNBG did not participate in the analysis or review of clinical trial data released by regulators in countries where its vaccine was being trialled, Yang said.

Source: bd News24 January 02, 2021 03:45 UTC